Table 2.
In situ production of cytokines and chemokines in 8 cutaneous leishmaniasis (CL) and 12 disseminated leishmaniasis (DL) patients
| Cytokine/chemokine (% of staining area) (median ± SD) | CL | DL papule | DL ulcer a |
|---|---|---|---|
| IFNγ | 19.2 ± 10.5 | 18.7 ± 6.1 | 18.9 ± 11.9 |
| TNFα | 14.2 ± 6.5 | 8.0 ± 10.4 | 13.3 ± 16.5 |
| IL-10 | 21.5 ± 12.6 | 17.6 ± 4.2 | 22.7 ± 15.4 |
| TGFβ | 16.8 ± 16.3 | 21.7 ± 8.8 | 35.9 ± 7.1 |
| CCL2 | 27.9 ± 10.4 | 16.7 ± 3.9 | 22.8 ± 10.9 |
| CCL3/MIP-1α | 12.4 ± 7.9 | 19.5 ± 7.5 | 19.1 ± 15 |
| CXCL10 | 17.6 ± 16.8 | 23.8 ± 3.4 | 23.1 ± 18.1 |
| Eotaxin | 25.8 ± 4.5 | 17.6 ± 5.9 | 23.8 ± 13 |
TGFβ: transforming growth factor-beta; CCL: chemokine (C-C motif) ligand; MIP-1α: macrophage inflammatory protein 1-alpha; CXCL: chemokine (C-X-C motif) ligand.
a
The P-value was > 0.05 when comparing the three groups.